Mechanisms of Immune Tolerance in Leukemia and Lymphoma

Trends in Immunology

Volumn 38, Issue 7, 2017, Pages 513-525

  Curran, Emily K ^a   Godfrey, James ^a   Kline, Justin ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD47 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERFERON; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; CD274 PROTEIN, HUMAN; PATTERN RECOGNITION RECEPTOR; PDCD1 PROTEIN, HUMAN;

CANCER IMMUNOTHERAPY; CELL EXPANSION; GENE; HUMAN; IMMUNE EVASION; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; INNATE IMMUNITY; LEUKEMIA; LYMPHOCYTE ACTIVATION GENE 3; LYMPHOMA; MYELOID-DERIVED SUPPRESSOR CELL; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; ANIMAL; ANTIGEN PRESENTING CELL; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; ANTIGEN-PRESENTING CELLS; B7-H1 ANTIGEN; GENE EXPRESSION REGULATION; HUMANS; IMMUNE EVASION; IMMUNE TOLERANCE; IMMUNOTHERAPY; LEUKEMIA; LYMPHOMA; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, PATTERN RECOGNITION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 85018868887     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2017.04.004     Document Type: Review

References (133)

1. Dunn, G.P., et al. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22 (2004), 329–360.
2. Hodi, F.S., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363 (2010), 711–723.
3. Robert, C., et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a Phase 1 trial. Lancet 384 (2014), 1109–1117.
4. Topalian, S.L., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366 (2012), 2443–2454.
5. Younes, A., et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm Phase 2 trial. Lancet Oncol. 17 (2016), 1283–1294.
6. Ansell, S.M., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372 (2015), 311–319.
7. Daver, N., et al. Phase IB/II study of nivolumab in combination with azacytidine (AZA) in patients (pts) with relapsed acute myeloid leukemia (AML). Blood, 128, 2016 763–763.
8. Lesokhin, A.M., et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a Phase Ib study. J. Clin. Oncol. 34 (2016), 2698–2704.
9. Ansell, S.M., et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin. Cancer Res. 15 (2009), 6446–6453.
10. Zhang, L., et al. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 114 (2009), 1545–1552.
11. + T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 117 (2011), 4501–4510.
12. Zhou, Q., et al. Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. Blood 114 (2009), 3793–3802.
13. high, regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients. Eur. J. Haematol. 75 (2005), 468–476.
14. Mussai, F., et al. Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood 122 (2013), 749–758.
15. Zhang, L., et al. CD40 ligation reverses T cell tolerance in acute myeloid leukemia. J. Clin. Invest. 123 (2013), 1999–2010.
16. Vardhana, S., Younes, A., The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints. Haematologica 101 (2016), 794–802.
17. Aldinucci, D., et al. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J. Pathol. 221 (2010), 248–263.
18. Kuppers, R., New insights in the biology of Hodgkin lymphoma. Hematol. Am. Soc. Hematol. Educ. Program 2012 (2012), 328–334.
19. Steidl, C., et al. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J. Clin. Oncol. 29 (2011), 1812–1826.
20. Liu, Y., et al. The microenvironment in classical Hodgkin lymphoma: an actively shaped and essential tumor component. Semin. Cancer Biol. 24 (2014), 15–22.
21. Niens, M., et al. Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. Br. J. Haematol. 140 (2008), 527–536.
22. Tanaka, A., Sakaguchi, S., Regulatory T cells in cancer immunotherapy. Cell Res. 27 (2016), 109–118.
23. Yaddanapudi, K., et al. Control of tumor-associated macrophage alternative activation by macrophage migration inhibitory factor. J. Immunol. 190 (2013), 2984–2993.
24. Juszczynski, P., et al. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 13134–13139.
25. Reichel, J., et al. Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed–Sternberg cells. Blood 125 (2015), 1061–1072.
26. Roemer, M.G., et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J. Clin. Oncol. 34 (2016), 2690–2697.
27. Green, M.R., et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116 (2010), 3268–3277.
28. Rooney, M.S., et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160 (2015), 48–61.
29. Sotomayor, E.M., et al. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood 98 (2001), 1070–1077.
30. Staveley-O'Carroll, K., Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 1178–1183.
31. Mottok, A., et al. Genomic alterations in CIITA are frequent in primary mediastinal large B cell lymphoma and are associated with diminished MHC class II expression. Cell Rep. 13 (2015), 1418–1431.
32. Leone, P., et al. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J. Natl. Cancer Inst. 105 (2013), 1172–1187.
33. Restifo, N.P., et al. Identification of human cancers deficient in antigen processing. J. Exp. Med. 177 (1993), 265–272.
34. Morin, R.D., et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476 (2011), 298–303.
35. Green, M.R., et al. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), E1116–E1125.
36. Twa, D.D., et al. Recurrent genomic rearrangements in primary testicular lymphoma. J. Pathol. 236 (2015), 136–141.
37. Brown, P.J., et al. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas. Leukemia 30 (2016), 605–616.
38. Masuda, K., et al. Loss or down-regulation of HLA class I expression at the allelic level in freshly isolated leukemic blasts. Cancer Sci. 98 (2007), 102–108.
39. Vago, L., et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N. Engl. J. Med. 361 (2009), 478–488.
40. Stolzel, F., et al. Clonal evolution including partial loss of human leukocyte antigen genes favoring extramedullary acute myeloid leukemia relapse after matched related allogeneic hematopoietic stem cell transplantation. Transplantation 93 (2012), 744–749.
41. McCurdy, S.R., et al. Loss of the mismatched human leukocyte antigen haplotype in two acute myelogenous leukemia relapses after haploidentical bone marrow transplantation with post-transplantation cyclophosphamide. Leukemia 30 (2016), 2102–2106.
42. Matsushita, H., et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482 (2012), 400–404.
43. Alexandrov, L.B., et al. Signatures of mutational processes in human cancer. Nature 500 (2013), 415–421.
44. Rizvi, N.A., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
45. Snyder, A., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371 (2014), 2189–2199.
46. Le, D.T., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372 (2015), 2509–2520.
47. Armand, P., et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J. Clin. Oncol. 34 (2016), 3733–3739.
48. Flavell, K.J., Murray, P.G., Hodgkin's disease and the Epstein–Barr virus. Mol. Pathol. 53 (2000), 262–269.
49. Obeid, M., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13 (2007), 54–61.
50. Apetoh, L., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13 (2007), 1050–1059.
51. Ghiringhelli, F., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors. Nat. Med. 15 (2009), 1170–1178.
52. Woo, S.R., et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41 (2014), 830–842.
53. Chen, D.S., Mellman, I., Oncology meets immunology: the cancer-immunity cycle. Immunity 39 (2013), 1–10.
54. Diamond, M.S., et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208 (2011), 1989–2003.
55. + dendritic cells. J. Exp. Med. 208 (2011), 2005–2016.
56. + dendritic cells in cytotoxic T cell immunity. Science 322 (2008), 1097–1100.
57. Curran, E., et al. STING pathway activation stimulates potent immunity against acute myeloid leukemia. Cell Rep. 15 (2016), 2357–2366.
58. Lewinsohn, M., et al. Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies. Blood 127 (2016), 1017–1023.
59. Polprasert, C., et al. Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell 27 (2015), 658–670.
60. Parvatiyar, K., et al. The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response. Nat. Immunol. 13 (2012), 1155–1161.
61. Zhang, Z., et al. The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells. Nat. Immunol. 12 (2011), 959–965.
62. Poon, I.K., et al. Apoptotic cell clearance: basic biology and therapeutic potential. Nat. Rev. Immunol. 14 (2014), 166–180.
63. Blazar, B.R., et al. CD47 (integrin-associated protein) engagement of dendritic cell and macrophage counterreceptors is required to prevent the clearance of donor lymphohematopoietic cells. J. Exp. Med. 194 (2001), 541–549.
64. Tsai, R.K., et al. Self inhibition of phagocytosis: the affinity of ‘marker of self’ CD47 for SIRPα dictates potency of inhibition but only at low expression levels. Blood Cells Mol. Dis. 45 (2010), 67–74.
65. Oldenborg, P.A., et al. Role of CD47 as a marker of self on red blood cells. Science 288 (2000), 2051–2054.
66. Tsai, R.K., Discher, D.E., Inhibition of “self” engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J. Cell Biol. 180 (2008), 989–1003.
67. Gardai, S.J., et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 123 (2005), 321–334.
68. Jaiswal, S., et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138 (2009), 271–285.
69. Chao, M.P., et al. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res. 71 (2011), 1374–1384.
70. Chao, M.P., et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142 (2010), 699–713.
71. Majeti, R., et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138 (2009), 286–299.
72. Weiskopf, K., et al. Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies. Science 341 (2013), 88–91.
73. Liu, X., et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat. Med. 21 (2015), 1209–1215.
74. Casey, S.C., et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352 (2016), 227–231.
75. Krampitz, G.W., et al. Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), 4464–4469.
76. Driessens, G., et al. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol. Rev. 229 (2009), 126–144.
77. Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12 (2012), 252–264.
78. Pauken, K.E., Wherry, E.J., Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 36 (2015), 265–276.
79. Topalian, S.L., et al. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27 (2015), 450–461.
80. Chemnitz, J.M., et al. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 173 (2004), 945–954.
81. Parry, R.V., et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 25 (2005), 9543–9553.
82. Yang, H., et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 28 (2014), 1280–1288.
83. Zhou, Q., et al. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood 116 (2010), 2484–2493.
84. Younes, A., et al. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J. Clin. Oncol. 30 (2012), 4161–4167.
85. Roemer, M.G.M., et al. Chromosome 9p24.1/PD-L1/PD-L2 alterations and PD-L1 expression and treatment outcomes in patients with classical Hodgkin lymphoma treated with nivolumab (PD-1 blockade). Blood, 128, 2016, 2923.
86. Chapuy, B., et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 127 (2016), 869–881.
87. Georgiou, K., et al. Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. Blood 127 (2016), 3026–3034.
88. Brunet, J.F., et al. A new member of the immunoglobulin superfamily – CTLA-4. Nature 328 (1987), 267–270.
89. Linsley, P.S., et al. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J. Exp. Med. 176 (1992), 1595–1604.
90. Collins, A.V., et al. The interaction properties of costimulatory molecules revisited. Immunity 17 (2002), 201–210.
91. Peach, R.J., et al. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1. J. Exp. Med. 180 (1994), 2049–2058.
92. + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192 (2000), 303–310.
93. + regulatory T cell function. Science 322 (2008), 271–275.
94. Leach, D.R., et al. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271 (1996), 1734–1736.
95. Marshall, N.A., et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 103 (2004), 1755–1762.
96. +, murine myelogenous leukemia. Blood 99 (2002), 2146–2153.
97. Ren, Z., et al. CTLA-4 limits anti-CD20-mediated tumor regression. Clin. Cancer Res. 23 (2017), 193–203.
98. Perez-Garcia, A., et al. CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy. Leukemia 23 (2009), 486–491.
99. Bashey, A., et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 113 (2009), 1581–1588.
100. Davids, M.S., et al. Ipilimumab for patients with relapse after allogeneic transplantation. N. Engl. J. Med. 375 (2016), 143–153.
101. Huard, B., et al. CD4/major histocompatibility complex class II interaction analyzed with CD4– and lymphocyte activation gene-3 (LAG-3)–Ig fusion proteins. Eur. J. Immunol. 25 (1995), 2718–2721.
102. Miyazaki, T., et al. Independent modes of natural killing distinguished in mice lacking Lag3. Science 272 (1996), 405–408.
103. Workman, C.J., et al. Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. J. Immunol. 172 (2004), 5450–5455.
104. Workman, C.J., Vignali, D.A., Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223). J. Immunol. 174 (2005), 688–695.
105. Woo, S.R., et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72 (2012), 917–927.
106. + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 7875–7880.
107. + T-cell tolerance. Cancer Res. 73 (2013), 605–616.
108. + T-cell function in Hodgkin lymphoma patients. Blood 108 (2006), 2280–2289.
109. Gajewski, T.F., et al. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14 (2013), 1014–1022.
110. Scott, D.W., Gascoyne, R.D., The tumour microenvironment in B cell lymphomas. Nat. Rev. Cancer 14 (2014), 517–534.
111. Fontenot, J.D., et al. Regulatory T cell lineage specification by the forkhead transcription factor Foxp3. Immunity 22 (2005), 329–341.
112. Sakaguchi, S., et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155 (1995), 1151–1164.
113. Sakaguchi, S., et al. Regulatory T cells and immune tolerance. Cell 133 (2008), 775–787.
114. Zou, W., Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6 (2006), 295–307.
115. + tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin. Cancer Res. 18 (2012), 3022–3029.
116. Turk, M.J., et al. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 200 (2004), 771–782.
117. Szczepanski, M.J., et al. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin. Cancer Res. 15 (2009), 3325–3332.
118. Attia, P., et al. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J. Immunother. 28 (2005), 582–592.
119. + regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 93 (2008), 193–200.
120. Alvaro, T., et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin. Cancer Res. 11 (2005), 1467–1473.
121. Greaves, P., et al. Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. J. Clin. Oncol. 31 (2013), 256–262.
122. Fowler, N.H., et al. Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica 101 (2016), 531–540.
123. + T cells. Sci. Transl. Med., 5, 2013, 200ra116.
124. Noy, R., Pollard, J.W., Tumor-associated macrophages: from mechanisms to therapy. Immunity 41 (2014), 49–61.
125. Steidl, C., et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N. Engl. J. Med. 362 (2010), 875–885.
126. Riihijarvi, S., et al. Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic Phase II trial. Haematologica 100 (2015), 238–245.
127. + T cells. Oncoimmunology, 2, 2013, e26968.
128. Ries, C.H., et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 25 (2014), 846–859.
129. Kumar, V., et al. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 37 (2016), 208–220.
130. Sun, H., et al. Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia. Int. J. Hematol. 102 (2015), 579–586.
131. Romano, A., et al. Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin lymphoma patients treated up-front with a risk-adapted strategy. Br. J. Haematol. 168 (2015), 689–700.
132. Draghiciu, O., et al. Myeloid derived suppressor cells – an overview of combat strategies to increase immunotherapy efficacy. Oncoimmunology, 4, 2015, e954829.
133. Qin, H., et al. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nat. Med. 20 (2014), 676–681.